文献速递肝病消化道肿瘤与早癌

既往治愈的肝细胞癌对非干扰素方案根除丙型肝炎感染后新发肝细胞癌的影响

Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments.
PubMed 文献 · Aliment Pharmacol Ther · 2018-07-25

本研究前瞻性纳入164例经无干扰素直接抗病毒药物(DAA)治疗获得持续病毒学应答(SVR)的HCV肝硬化患者,比较有既往治愈HCC史(n=62)与无HCC史(n=102)患者SVR后基于钆塞酸二钠增强磁共振成像(EOB-MRI)的HCC发生模式差异。结果显示有HCC史患者SVR后HCC发生率更高(P<0.0001),基线非富血供低信号结节(NHHN)患病率更高(P=0.05),且无基线NHHN时直接出现富血供HCC的发生率显著更高(P<0.0001)。

要点

  • 有既往治愈HCC史患者DAA治疗获SVR后HCC发生率高于无HCC史患者(P<0.0001)。
  • 有HCC史患者基线EOB-MRI检出的NHHN患病率显著更高(P=0.05)。
  • 无基线NHHN时直接出现富血供HCC的发生率在有HCC史患者中显著更高(P<0.0001)。

核心结论

  • 直接出现富血供HCC及DAA治疗前NHHN患病率较高,共同导致有既往治愈HCC史患者SVR后HCC发生率更高。

研究设计与样本

  • 前瞻性研究,纳入164例经无干扰素DAA治疗获SVR的HCV肝硬化患者,在治疗开始前进行EOB-MRI。
  • 比较有HCC史组(n=62)与无HCC史组(n=102)SVR后EOB-MRI表现的变化。

主要发现

  • 有HCC史组SVR后HCC发生率高于无HCC史组(P<0.0001)。
  • 有HCC史组基线NHHN患病率显著高于无HCC史组(P=0.05)。
  • 两组间基线NHHN富血供化转为典型富血供HCC的发生率无差异。
  • 无基线NHHN时直接出现富血供HCC的发生率在有HCC史组显著高于无HCC史组(P<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of hepatocellular carcinoma (HCC) in patients with a history of curatively-treated HCC is higher than in patients with no history of HCC even after sustained virologic response (SVR). AIM: To investigate differences in the patterns of HCC development after SVR in patients with a history of curatively-treated HCC and those with no history of HCC, based on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) findings. METHODS: EOB-MRI was performed in 164 patients with HCV cirrhosis who achieved SVR by interferon-free direct-acting antiviral (DAA) therapy just before the start of therapy. Changes in EOB-MRI findings after SVR were compared prospectively between patients with (n = 62) and without (n = 102) a history of HCC. RESULTS: The incidence of HCC after SVR was higher in patients with a history of HCC (P < 0.0001). The prevalence of nonhypervascular hypointense nodules (NHHNs) by EOB-MRI was significantly higher in patients with a history of HCC at baseline (P = 0.05). Although there was no difference in the incidence of the hypervascularisation of baseline NHHNs to typical hypervascular HCC between patients with and without a history of HCC, the incidence of direct emergence of hypervascular HCC despite the absence of NHHNs at baseline was significantly higher in patients with a history of HCC (P < 0.0001). CONCLUSION: Direct emergence of hypervascular HCC and a higher prevalence of NHHNs before DD therapy contributed to the higher incidence of HCC after SVR. (UMIN000017020).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Toyoda H, Kumada T, Tada T, et al. Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments. Aliment Pharmacol Ther. 2018. PMID: 30047149. doi:10.1111/apt.14914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。